EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) ASMONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSETSEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED,PARALLEL-GROUP, MULTICENTER CLINICAL STUDY

BIAL Portela Ca SA0 个研究点目标入组 900 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•For inclusion in the study, subjects must fulfill all of the following at the time points
•Visit 1 (Days ?1 to ?7; Screening)
•1. Have signed an informed consent before undergoing any study-related activities.
•Subjects of Asian ancestry (subjects with a direct ancestor of Asian origin, irrespective of the generational difference) are required to give written informed consent for genotyping.
•2. Male or female above18 years of age.
•3. Newly diagnosed epilepsy with at least 2 well documented, unprovoked, clinically
•evaluated and classified partial seizures (with or without secondary generalization) with clear focal origin, documented clinically OR by electroencephalogram (EEG) OR imaging studies, within 12 months of Visit 1. In this context, seizures that occur within a period of 48 hours are counted as 1seizure.
•4. At least 1 seizure during the previous 3 months.
•5. Demonstrated cooperation and willingness to complete all aspects of the study.
•6. Female subjects without childbearing potential (2 years postmenopausal, bilateral oophorectomy or tubal ligation, or complete hysterectomy) are eligible. Female subjects with childbearing potential must not be pregnant as confirmed by a negative serum â-human chorionic gonadotropin (hCG) test and sexually active females must be using a medically acceptable effective non-hormonal method of contraception for the duration of the study and until the Post-study visit (PSV).
•Visit A1 (Day 1; Randomization and start of double-blind treatment period)
•7. Have satisfactorily completed the electronic subject diary (eDiary).
•8. Female subjects with childbearing potential must not be pregnant as confirmed by a negative urine pregnancy test and sexually active females must be using a medically acceptable effective non-hormonal method of contraception for the duration of the study and until the PSV.

排除标准

•Subjects having any of the following at the time points indicated are to be excluded
•from the study.
•Visit 1 (Days ?1 to ?7; Screening)
•1. History of pseudo-seizures.
•2. Seizures occurring only in clusters.
•3. History of absence, myoclonic, clonic, tonic, or atonic seizures.
•4. Documented EEG within 12 months of Visit 1 suggestive of primarily generalized epilepsy.
•5. History of status epilepticus within the 3 months prior to Visit 1.
•6. Known progressive neurologic disorder (progressive brain disease, epilepsy secondary to progressive cerebral lesion) as assessed by magnetic resonance imaging or computer tomography.
•7. Former or current use of any AED, except for the use of a single AED for a maximum duration of 2 weeks before Visit 1.
•8. Previous use of ESL or CBZ.
•9. Using mono-amine oxidase inhibitors (MAOIs), tricyclic antidepressants, nefazodone, isoniazid, or protease inhibitors or any other anti-retroviral agents (e.g. efavirez) that may raise the levels of CBZ-CR.
•10. Known hypersensitivity to carboxamide derivatives or tricyclic antidepressants.
•11. History of uncontrolled psychiatric illness or mood disorder requiring electroconvulsive or drug therapy within the previous 6 months, a history of suicide attempt, schizophrenia, chronic treatment with benzodiazepines (except shortacting benzodiazepines) or barbiturates.
•12. Judged clinically to have a suicidal risk in the opinion of the investigator based upon a clinical interview and the Columbia Suicide-Severity Rating Scale (CSSRS).
•13. History of alcohol, drug, or medication abuse within the last 2 years.
•14. Uncontrolled cardiac (including atrioventricular block and other clinically significant electrocardiographic abnormalities), renal, hepatic, endocrine, gastrointestinal, metabolic, hematological, or oncology disorder.
•15. History of bone marrow depression.
•16. History of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda).
•17. Relevant clinical laboratory abnormalities (e.g. sodium less than 130 mmol/L, alanine or aspartate transaminases grater than 2 x the upper limit of normal, white blood cell count less than 3000 cells/mm3) (measured at Visit 1).
•18. Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (measured at Visit 1).
•19. Subjects of Asian ancestry who test positive for the presence of the HLA-B1502 allele.
•20. Pregnancy or lactating.
•21. Participation in other drug clinical trial within the last 2 months or having received an IMP within 5 half-lives of that IMP, whichever is longer.
•22. Any other condition or circumstance that, in the opinion of the investigator, could compromise the subject?s ability to comply with the study protocol.
•Visit A1 (Day 1; Randomization and start of double-blind treatment period)
•23. Former or current use of any AED, except for the use of a single AED for a maximum duration of 2 weeks before Visit 1 and with a drug-free period of at least 5 days before Visit A1. Benzodiazepines are allowed, no more than twice a week, for an epileptic indication and as rescue medication during the grater than and equal to 5-day drugfree period.
•24. Using prohibited medication.
•25. Pregnancy.
•26. Any other condition or circumstance that, in the opinion of the investigator, could com

研究者

发起方

BIAL Portela Ca SA

相似试验

进行中（未招募）

不适用

EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093)AS THERAPY FOR PATIENTS WITH PAINFUL DIABETIC NEUROPATHY:A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAadult patients with painful diabetic neuropathyMedDRA version: 9.1Level: PTClassification code 10012680Term: Diabetic neuropathy

EUCTR2007-002461-12-PTBIAL - Portela & Ca, S.A.540

已完成

不适用

EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES:A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY-G40G40

PER-108-10BIAL - Portela & Cª, S.A.,13

进行中（未招募）

1 期

EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURESAdult patients with newly diagnosed partial-onset seizuresMedDRA version: 18.1Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852

EUCTR2009-011135-13-CZBIAL - Portela & Ca, S.A.900

进行中（未招募）

不适用

EUCTR2007-002461-12-CZBIAL - Portela & Ca, S.A.540

进行中（未招募）

1 期

EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAL.

EUCTR2008-002455-25-CYBIAL - Portela & Cª, SA360